相关实验视频

Updated: Jan 13, 2026

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Published on: January 17, 2025

对于急性不补偿性心力衰竭的体外膜氧化:鼓励长期结果

Ahmed M El Banayosy¹, Joseph M Brewer¹, Luke C Cunningham¹

¹INTEGRIS Baptist Medical Center, INTEGRIS Health, Inc., Oklahoma City, OK, USA.

The International journal of artificial organs

|January 7, 2026

概括

静脉ECMO有效地支持患有急性不补偿性心力衰竭的心脏性休克的患者,提供恢复或先进治疗的桥梁,如持久的MCS或心脏移植.

科学领域:

心脏病学心脏病学
关键护理医学关键护理医学
机械循环支持机械循环支持

背景情况:

在急性不补偿性心力衰竭 (ADHF) 中,心脏性休克 (CS) 是一种需要机械循环支持 (MCS) 的关键状况.
静脉外体膜氧化 (VA ECMO) 是CS的主要临时MCS选择.
这项研究评估了VA ECMO在ADHF-CS患者的结果.

研究的目的:

评估VA ECMO在患有ADHF二次性CS的患者的疗效和结果.
为了确定医院出院和治疗后2年的生存率.
在这个患者群体中识别与VA ECMO相关的并发症.

主要方法:

一项追溯观察队列研究,涉及69名ADHF-CS需要VA ECMO的成人患者,从2014年至2023年.
排除标准包括体外心肺复苏 (ECPR) 和初始静脉静脉 (VV) ECMO.
分析基线特征,ECMO支持细节和临床结果,包括存活到出院和2年存活率.

主要成果:

在所有患者中,VA ECMO是从外围开始的,平均支持持续时间为10天.
在73.9%的患者中,ECMO的成功断奶发生了.
医院出院生存率为56.5%,两年生存率为46.3%.
36.2%的患者经历了长期的MCS,16%的患者被奶并存活下来,13%的患者接受了心脏移植.
常见的并发症包括置换疗法 (34.8%),出血 (20.3%) 和感染 (16%).
神经事件,出血和置换疗法与较差的结果有关.

结论:

对于ADHF-CS来说,VA ECMO是一个可行的短期支持战略.
它有效地将患者连接到康复或先进疗法.
仔细监测并发症对于改善患者的治疗结果至关重要.

关键词:

在MCS中使用MCS.VA ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO ECMO 从急性到慢性心力衰竭.心脏发生的冲击是心脏发生的冲击.

更多相关视频

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse

Published on: October 24, 2018

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

相关概念视频

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Acute Respiratory Failure-II

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

Acute Respiratory Failure-III

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Acute Respiratory Failure-IV

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...